Shattuck Labs

Shattuck Labs

Biotechnology
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

$467.5M

Market Cap • 11/17/2026

2016

(10 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

1,9

EPS

—

Market Cap

Market Cap

467,5M

EV

407,3M

EV/Revenue

—

EV/EBITDA

-5,9

EV/EBIT

-5,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-33,9%

Total Yield

-33,9%

Payout

0%

Retained Earnings

-485,7M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

5,5%

Capex/OCF

-0,4%

SBC/OCF

—

% PPE

1,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

1,6%

CAGR Net Income 5Y

0,4%

CAGR EPS 5Y

-21,9%

CAGR OCF 5Y

-1,1%

Leverage

N.D./EBITDA

0,9

Debt/Equity

0%

Current Ratio

5,3

Quick Ratio

4,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium